AR
BCRX icon

Advisory Research’s BioCryst Pharmaceuticals BCRX Stock Holding History

Advisory Research’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-80,482
Closed -$1.31M – 376
2022
Q1 		$1.31M Buy
+80,482
New +$1.29M 0.1% 156

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advisory Research's BCRX Position: Q2 2022 in Review

Advisory Research sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 80,482 shares — an estimated $1.31M sold.

Advisory Research first reported a position in BCRX in Q1 2022 and held it in 1 quarter. The position peaked at $1.31M in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Advisory Research reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Advisory Research sold 80,482 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $1.31M.
  • Advisory Research first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Advisory Research's BioCryst Pharmaceuticals position peaked at $1.31M in Q1 2022.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Advisory Research's 13F filing for Q2 2022, filed 15 Aug 2022.